Updated Oct 20, 2026
/ConnectM appoints three executives to new advisory board/Nasdaq Rises 1.1% in Relief Rally Ahead of Big Tech Earnings/Rams receiver Davante Adams out 6-10 weeks with hamstring rupture/CDW appoints former Deloitte chief Sam Balaji to board/Copper outperforms gold as AI and defense demand surge/RLI Corp. third-quarter net earnings fall to $81.0 million/ConnectM appoints three executives to new advisory board/Nasdaq Rises 1.1% in Relief Rally Ahead of Big Tech Earnings/Rams receiver Davante Adams out 6-10 weeks with hamstring rupture/CDW appoints former Deloitte chief Sam Balaji to board/Copper outperforms gold as AI and defense demand surge/RLI Corp. third-quarter net earnings fall to $81.0 million
NewsSOS
← NewswireMarkets

Purcell & Lefkowitz opens shareholder probe into AN2 Therapeutics directors

NEW YORK, July 20. Purcell & Lefkowitz LLP disclosed Sunday it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders, with the inquiry focused on whether the biotech's directors breached their fiduciary duties. The New York law firm provided no further detail on what specific conduct or corporate action prompted the probe.

By Hannah Voss2 min read
Share

Key takeaways

  • Purcell & Lefkowitz LLP disclosed on Sunday, July 20, that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders.
  • The probe focuses on whether AN2 Therapeutics's directors breached their fiduciary duties.
  • The New York law firm did not identify specific board members, transactions, or decisions under review.
  • No timeline for the investigation was provided in the firm's disclosure.
  • AN2 Therapeutics trades on the Nasdaq under the ticker symbol ANTX.

NEW YORK, July 20. Purcell & Lefkowitz LLP disclosed Sunday it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders, with the inquiry focused on whether the biotech's directors breached their fiduciary duties. The New York law firm provided no further detail on what specific conduct or corporate action prompted the probe.

The inquiry

The investigation centers on potential fiduciary duty breaches by AN2 Therapeutics's board of directors, according to the firm's announcement. Purcell & Lefkowitz did not identify specific board members by name or disclose which transactions or decisions are under review.

No timeline for the investigation was provided in the firm's disclosure.

AN2 Therapeutics

AN2 Therapeutics is listed on the Nasdaq under the ticker symbol ANTX. The firm's announcement stated the investigation is being conducted on behalf of ANTX shareholders.

Note: The source summary is limited. This article reports only the facts disclosed. No figures, transaction details, or additional context were available in the source material.

Keep reading

All bulletins →
MarketsOctober 20, 2026

Singapore Ag Stocks Fall After Minister Warns on Haze Responsibility

Shares of Singapore-listed agricultural companies declined Tuesday after Senior Minister K Shanmugam warned that firms cannot evade responsibility for their role in the haze affecting the city-state. Shanmugam stated that seven companies…

2 min read
MarketsOctober 18, 2026

Nasdaq adds Moderna to 100 index, triggering ETF purchases

Nasdaq Inc. added Moderna to the Nasdaq-100 index earlier this month. The index tracks the 100 largest non-financial listings on the Nasdaq Stock Market. This inclusion requires exchange-traded fund managers to purchase Moderna stock to…

2 min read
MarketsOctober 17, 2026

Investor Allocates $4,600 to Abbott, P&G, Paychex Dividend Plays

An investor has allocated more than $4,600 across shares of Abbott, Procter & Gamble, and Paychex, shifting portfolio weight toward defensive dividend stocks in response to elevated market valuations and recent Federal Reserve rate hikes…

2 min read

Frequently asked

Who is being investigated and by whom?

The New York law firm Purcell & Lefkowitz LLP is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders.

What is the investigation about?

It centers on whether AN2 Therapeutics's board of directors breached their fiduciary duties.

Did the firm name specific directors or transactions?

No, Purcell & Lefkowitz did not identify specific board members by name or disclose which transactions or decisions are under review.

When was the investigation disclosed?

The firm disclosed the investigation on Sunday, July 20, from New York.

Was a timeline given for the investigation?

No timeline for the investigation was provided in the firm's disclosure.